We are focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.

Our technology

The unique potential of Radiopharmaceuticals in treating oncological diseases.

Learn more

Our pipeline

The unique potential of being First to Market or Best in Class.

Learn more

Our team

We have a unique commitment to improve patients’ hope in fighting cancer.

Learn more

Information for investors

Stock price, Company governance & updates from our multiple development programs.

Learn more

Latest news

ASX Releases

Dr Susann Brady-Kalnay appointed to RAD Scientific Advisory Board

June 21, 2022

Read moreRead more

ASX Releases

Investor Webinar - CEO and Riccardo Canevari and Dr Susann Brady-Kalnay to discuss promising radiopharmaceutical agent recently added to the RAD Portfolio

June 15, 2022

Read moreRead more

ASX Releases

Radiopharm and Isotopia announce supply agreement for Lutetium-177 N.C.A

June 14, 2022

Read moreRead more